Signal Genetics LLC To Present At The Aegis Capital Corp. 2014 Healthcare & Technology Conference
CARLSBAD, Calif., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced that Samuel D. Riccitelli, President and Chief Executive Officer of Signal, will present a corporate overview at the Aegis Capital Corp. 2014 Healthcare & Technology Conference being held on September 10 -13, 2014 at the Encore at Wynn Hotel in Las Vegas, Nevada.
Details of the presentation are as follows:
Date: Thursday, September 11, 2014
Time: 3:00 p.m. P.T.
Place: Encore at Wynn Las Vegas
About Signal Genetics, Inc.
Signal Genetics, Inc., headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The Company's mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Signal was founded in January 2010 and became the exclusive licensee in its licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, or UAMS, in April 2010.
CONTACT: INVESTOR CONTACT: The Ruth Group David Burke Tel: 646-536-7009 dburke@theruthgroup.com